Company intelligence / Profile preview

12-15 Molecular Diagnostics

East Haven, Connecticut, United States12-15mds.com ↗

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

The Veralize® platform demonstrated up to 98% accuracy in NY/CT clinical trials for COVID‑19 using a rapid saliva test. The device delivers results within minutes and has been validated against PCR standards. It is also being developed for broader applications including water quality and food safety testing[1][2].

Therapeutic areas: Infectious Diseases
Modalities: DeviceNanotechnology-based diagnostic platform (carbon-based nanomaterial)
Industry: Molecular Diagnostics

Partnerships

National Institutes of Health (NIH) – grant funding for COVID‑19 test development[1]

Beyond the preview

Go deeper on 12-15 Molecular Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 12-15 Molecular Diagnostics.

Explore the full profile